Emergent BioSolutions (EBS) Net Margin (2011 - 2026)
Emergent BioSolutions' (EBS) quarterly Net Margin came in at 4.36% in Q1 2026, down 2625.0% year-on-year from 0.17% in Q1 2025, and up 111.86% quarter-over-quarter from 36.72% in Q4 2025.
Emergent BioSolutions (EBS) Net Margin (2011 - 2026) Analysis & Trends
Emergent BioSolutions' Net Margin history runs 15 years deep, the most recent figure standing at 4.36% for Q1 2026.
- On a quarterly basis, Net Margin fell 2625.0% year-over-year to 4.36% in Q1 2026; TTM through Mar 2026 was 1.27%, a 1603.0% increase from a year earlier, with the FY2025 full-year figure at 7.08%, up 2534.0% from the prior year.
- Net Margin advanced to 4.36% in Q1 2026 per EBS's latest filing, from 36.72% in the prior quarter.
- Across five years, Net Margin topped out at 39.07% in Q3 2024 and bottomed at 566.2% in Q2 2024.
- The 5-year median for Net Margin is 17.9% (2023), against an average of 53.84%.
- Across the five-year window, Net Margin tumbled 48884 bps in 2024 and jumped 55768 bps in 2025, its largest moves.
- Year by year, Net Margin stood at 20.29% in 2022, then grew by 12 bps to 17.9% in 2023, then grew by 10 bps to 16.08% in 2024, then tumbled by 128 bps to 36.72% in 2025, then jumped by 112 bps to 4.36% in 2026.
- Per Business Quant, the three latest EBS Net Margin figures stand at 4.36% (Q1 2026), 36.72% (Q4 2025), and 22.15% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 9.29% |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 26.57% |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -33.66% |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 35.18% |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 5.03% |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 24.30% |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 4.16% |
| 10 | Emergent BioSolutions | 376.02 Mn | 214.52 Mn | 84.10 Mn | 4.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.36% |
| Dec 31, 2025 | -36.72% |
| Sep 30, 2025 | 22.15% |
| Jun 30, 2025 | -8.52% |
| Mar 31, 2025 | 30.60% |
| Dec 31, 2024 | -16.08% |
| Sep 30, 2024 | 39.07% |
| Jun 30, 2024 | -566.20% |
| Mar 31, 2024 | 3.00% |
| Dec 31, 2023 | -17.90% |
| Sep 30, 2023 | -97.38% |
| Jun 30, 2023 | -77.36% |
| Mar 31, 2023 | -113.33% |
| Dec 31, 2022 | -20.29% |
| Sep 30, 2022 | -36.31% |
| Jun 30, 2022 | -23.25% |
| Mar 31, 2022 | -1.21% |
| Dec 31, 2021 | 24.27% |
| Sep 30, 2021 | -11.42% |
| Jun 30, 2021 | 1.22% |